Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mucin glycoproteins are large, heavily O-glycosylated proteins secreted primarily by goblet cells and submucosal gland cells in the airway epithelium. The most clinically important airway mucins are MUC5AC and MUC5B, which polymerize to form a gel-like mucus layer atop the respiratory epithelium. This mucus protects against inhaled pathogens, particles, and environmental insults while ensuring airway hydration and supporting mucociliary transport. Mucin synthesis and secretion are tightly regulated and are dramatically upregulated in response to airway inflammation, infection, and irritants. Dysregulation of mucin production or mucus clearance contributes to disease pathogenesis in asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and other respiratory conditions. Therapeutic interventions target mucin gene expression, secretion, or the physical properties of mucus to restore airway homeostasis or improve symptoms.
Mucolytics: disrupt mucin polymer and reduce viscosity Anti-inflammatories: suppress mucin gene expression Hydrators: draw water into mucus to aid clearance
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mucin glycoproteins (airway).